-+ 0.00%
-+ 0.00%
-+ 0.00%

IGC Pharma Completes Dosing in Phase 2 Trial of IGC-AD1 for Alzheimer's Agitation

PUBT·11/18/2026 13:02:02
Diffusion vocale
IGC Pharma Completes Dosing in Phase 2 Trial of IGC-AD1 for Alzheimer's Agitation
  • IGC Pharma completed six weeks of dosing in all 170 participants in its Phase 2 CALMA trial for agitation in Alzheimer's dementia.
  • Enrollment exceeded the original target of 146 participants across sites in the United States and Canada.
  • The trial evaluates investigational oral liquid IGC-AD1 against placebo for reducing agitation.
  • Topline results are expected in December 2026 or January 2027 following database lock, unblinding and independent statistical analysis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611180800ACCESSWRNAPR_____1253231) on November 18, 2026, and is solely responsible for the information contained therein.